KindlyMD, Inc. (NASDAQ:NAKA) Given Consensus Rating of “Hold” by Brokerages

KindlyMD, Inc. (NASDAQ:NAKA) has been assigned an average rating of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $22.3333.

Several research firms have recently commented on NAKA. TD Cowen increased their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th.

KindlyMD Trading Down 1.2%

NASDAQ:NAKA opened at $4.94 on Thursday. The firm has a 50-day moving average price of $4.37 and a two-hundred day moving average price of $7.65. KindlyMD has a twelve month low of $3.33 and a twelve month high of $624.00. The company has a market capitalization of $85.97 million, a P/E ratio of -0.11 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. The business had revenue of $2.68 million during the quarter. On average, equities research analysts predict that KindlyMD will post -16.8 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO David F. Bailey purchased 104,833 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was bought at an average cost of $4.84 per share, with a total value of $507,391.72. Following the completion of the acquisition, the chief executive officer directly owned 3,120,361 shares in the company, valued at $15,102,547.24. The trade was a 3.48% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 191,448 shares of company stock worth $992,908 over the last ninety days. Company insiders own 24.49% of the company’s stock.

Institutional Trading of KindlyMD

A number of large investors have recently made changes to their positions in NAKA. Alyeska Investment Group L.P. purchased a new stake in KindlyMD during the 4th quarter worth about $8,993,000. ParaFi Capital LP purchased a new position in KindlyMD in the 3rd quarter valued at about $443,055,000. Hunting Hill Global Capital LLC purchased a new position in KindlyMD in the 4th quarter valued at about $4,672,000. Yorkville Advisors Global LP acquired a new stake in shares of KindlyMD during the 4th quarter worth about $3,265,000. Finally, UBS Group AG acquired a new stake in shares of KindlyMD during the 4th quarter worth about $2,958,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.